Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2011 Aug;26(8):2200-8.
doi: 10.1093/humrep/der163. Epub 2011 May 27.

Repeated ovarian stimulation with corifollitropin alfa in patients in a GnRH antagonist protocol: no concern for immunogenicity

Robert J Norman  1 , Fernando Zegers-Hochschild, Bruno S Salle, Jolanda Elbers, Esther Heijnen, Maya Marintcheva-Petrova, Bernadette Mannaerts; Trust Investigators
Affiliations
Clinical Trial

Repeated ovarian stimulation with corifollitropin alfa in patients in a GnRH antagonist protocol: no concern for immunogenicity

Robert J Norman et al. Hum Reprod. 2011 Aug.

Abstract

Background: One injection of corifollitropin alfa replaces the first seven daily FSH injections in controlled ovarian stimulation (COS) cycles. Repeated treatment with therapeutic proteins may cause immune responses or hypersensitivity reactions. We assessed the immunogenicity and safety of corifollitropin alfa treatment in up to three COS cycles.

Methods: In this multicentre, phase III uncontrolled trial, patients (>60 kg) started treatment with one injection of 150 µg corifollitropin alfa on cycle Day 2 or 3 of menses and 0.25 mg ganielix on stimulation Day 5 or 6. Primary outcome measures were antibody formation against corifollitropin alfa (using highly sensitive radioimmunoprecipitation assay), hypersensitivity reactions, local tolerance and adverse events (AEs).

Results: First, second and third COS cycles were started by 682, 375 and 198 patients, respectively. No clinically relevant immunogenicity or drug-related hypersensitivity was observed. For 192 patients undergoing their third cycle a post-treatment blood sample was negative in the anti-corifollitropin antibody assay, resulting in an upper limit of the one-sided 95% confidence interval (CI) of 1.5%. Most frequent AEs were procedural pain (17.7%, 95% CI: 14.9-20.8%), headache (9.1%, 95% CI: 7.0-11.5%) and pelvic pain (7.6%, 95% CI: 5.7-9.9%). Cumulative ongoing pregnancy rate after three cycles, including frozen-thawed embryo transfer cycles and spontaneous pregnancies, was 61% (95% CI: 56-65%) after censoring for patients who discontinued.

Conclusions: Treatment with corifollitropin alfa can safely and effectively initiate and sustain ovarian stimulation during the first 7 days of COS in normal responder patients undergoing up to three treatment cycles, without concerns of immunogenicity. The trial was registered under ClinicalTrials.gov identifier NCT00696878.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Treatment scheme during the first stimulation cycle. In case patients did not become pregnant, the same treatment was applied in the second and third stimulation cycle. Between two treatment cycles patients could have replacement of cryopreserved oocytes or embryos obtained in a previous treatment cycle. ET, embryo transfer; rFSH, recombinant FSH.
Figure 2
Figure 2
Flow of patients through the treatment cycles. FTET, frozen-thawed embryo transfer.
See this image and copyright information in PMC

References

    1. Amato F, Warnes GM, Kirby CA, Norman RJ. Infertility caused by hCG autoantibody. J Clin Endocrinol Metab. 2002;87:993–997. - PubMed
    1. Baker VL, Jones CE, Cometti B, Hoehler F, Salle B, Urbancsek J, Soules MR. Factors affecting success rates in two concurrent clinical IVF trials: an examination of potential explanations for the difference in pregnancy rates between the United States and Europe. Fertil Steril. 2010;94:1287–1291. - PubMed
    1. Bouloux PM, Handelsman DJ, Jockenhöl F, Nieschlag E, Rabinovici J, Frasa WL, de Bie JJ, Voortman G, Itskovitz-Eldor J FSH-CTP study group. First human exposure to FSH-CTP in hypogonadotrophic hypogonal males. Hum Reprod. 2001;16:1592–1597. - PubMed
    1. De Greef R, Zandvliet A, de Haan A, IJzerman-Boon P, Marintcheva-Petrova M, Mannaerts B. Dose selection of corifollitropin alfa by modeling and simulation in controlled ovarian stimulation. Clin Pharmacol Ther. 2010;88:79–87. - PubMed
    1. Devroey P, Boostanfar R, Koper NP, Mannaerts BM, Ijzerman-Boon PC, Fauser BC on behalf of the ENGAGE Investigators. A double-blind, non-inferiority RCT comparing corifollitropin alfa and recombinant FSH during the first seven days of ovarian stimulation using a GnRH antagonist protocol. Hum Reprod. 2009;24:3063–3072. - PMC - PubMed

Publication types

Substances

Associated data